As an application of ELP biomaterials, our lab is focusing on the development of immunotherapy delivery platforms. Through the genetic and chemical modification, we can engineer ELPs to modulate the immune system at multiple stages of the cancer immunity cycle. Enhanced delivery of immunomodulatory molecules with ELPs can promote: 1) release and presentation of cancer antigens, 2) priming and recruitment of immune cells, 3) infiltration of immune cells to tumor microenvironments, 4) recognition of cancer cells by T cells, and 5) immunogenic death of cancer cells. We are utilizing ELP-based delivery platforms for novel combination therapies to generate robust anti-cancer immune responses for the eradication of established tumors.

ELP-based platfoms graphic


E. M. Mastria, Cai, L. Y. , Li, X. , Schaal, J. L. , and Chilkoti, A. , "Nanoparticle formulation improves doxorubicin efficacy by enhancing host antitumor immunity”, Journal of Controlled Release, vol. 269, pp. 364-373, 2018.


Immune-active polymeric materials for the treatment of inflammatory diseases. K.M. Lazar; S. Shetty; A. Chilkoti; J.H. Collier. (2023).
Brachytherapy via a depot of biopolymer-bound 131I synergizes with nanoparticle paclitaxel in therapy-resistant pancreatic tumours. J.L. Schaal; J. Bhattacharyya; J. Brownstein; K.C. Strickland; G. Kelly; S. Saha; J. Milligan; S. Banskota; X. Li; W. Liu; D.G. Kirsch; M.R. Zalutsky; A. Chilkoti. (2022).
Long circulating genetically encoded intrinsically disordered zwitterionic polypeptides for drug delivery. S. Banskota; P. Yousefpour; N. Kirmani; X. Li; A. Chilkoti. (2019).